Spleen tyrosine kinase (SYK) (SYK)

Spleen tyrosine kinase (SYK) is a 72 kDa non-receptor cytoplasmic tyrosine kinase that plays a pivotal role in the signal transduction of various immunoreceptors, including the B-cell receptor (BCR) and Fc receptors (UniProt P43405). It is primarily expressed in hematopoietic cells such as B cells, mast cells, macrophages, and neutrophils, where it serves as a key mediator of immune cell activation and inflammatory responses (PubMed: 25633470). Upon receptor engagement, SYK is recruited to phosphorylated immunoreceptor tyrosine-based activation motifs (ITAMs), triggering downstream cascades like the PI3K/Akt and MAPK pathways (NCBI Gene: 6850). These processes are essential for B-cell development, platelet activation, and the production of pro-inflammatory cytokines. Dysregulation or overexpression of SYK is implicated in several diseases, particularly B-cell malignancies, rheumatoid arthritis, and immune thrombocytopenia (ITP) (StatPearls: NBK541014). Consequently, SYK has emerged as a significant therapeutic target, with inhibitors like fostamatinib approved for clinical use to modulate immune-mediated destruction and treat hematologic conditions (FDA).

Other names

p72-SykSpleen tyrosine kinaseSYK

SYK inhibitors typically function as ATP-competitive inhibitors that bind to the kinase domain of the enzyme, preventing the phosphorylation of downstream signaling proteins and effectively blocking signal transduction from immunoreceptors such as the B-cell receptor (BCR) and Fc receptors.